Find Relebactam manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1174018-99-5, Mk-7655, Relebactam anhydrous, Relebactam [inn], (-)-relebactam anhydrous, 1oqf7tt3pf
Molecular Formula
C12H20N4O6S
Molecular Weight
348.38  g/mol
InChI Key
SMOBCLHAZXOKDQ-ZJUUUORDSA-N
FDA UNII
1OQF7TT3PF

Relebactam
Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam]. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes [imipenem] and [cilastatin] to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated intra-abdominal infections in adults. It is considered to be a last-line treatment option and gained FDA approval as part of the combination product Recarbrio in July 2019.
1 2D Structure

Relebactam

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
2.1.2 InChI
InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1
2.1.3 InChI Key
SMOBCLHAZXOKDQ-ZJUUUORDSA-N
2.1.4 Canonical SMILES
C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
2.1.5 Isomeric SMILES
C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
2.2 Other Identifiers
2.2.1 UNII
1OQF7TT3PF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2s,5r)-7-oxo-n-(4-piperidinyl)-6-(sulfooxy)-1,6-diazabicyclo(3.2.1)octane-2-carboxamide

2. Mk-7655

3. Mk7655

4. Relebactam Anhydrous

2.3.2 Depositor-Supplied Synonyms

1. 1174018-99-5

2. Mk-7655

3. Relebactam Anhydrous

4. Relebactam [inn]

5. (-)-relebactam Anhydrous

6. 1oqf7tt3pf

7. Chembl3112741

8. Mk-7655a

9. Mk7655

10. Sulfuric Acid Mono-((2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) Ester

11. (1r,2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl Hydrogen Sulfate

12. [(2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] Hydrogen Sulfate

13. Unii-1oqf7tt3pf

14. Relebactam [mi]

15. Relebactam [who-dd]

16. Bdbm1858

17. Schembl3721178

18. Gtpl10852

19. Ex-a864

20. Sulfuric Acid Mono-[7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo[3.2.1]oct-6-yl] Ester

21. Bdbm50447651

22. Mfcd28502833

23. Zinc43206319

24. Cs-5391

25. Db12377

26. Ac-36163

27. As-35205

28. Br163749

29. Hy-16752

30. Us8487073, 1a

31. S0074

32. J3.628.086g

33. Mk-7655;mk7655;mk 7655

34. J-690043

35. Q27252695

36. (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

2.4 Create Date
2009-08-03
3 Chemical and Physical Properties
Molecular Weight 348.38 g/mol
Molecular Formula C12H20N4O6S
XLogP3-3.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count4
Exact Mass348.11035554 g/mol
Monoisotopic Mass348.11035554 g/mol
Topological Polar Surface Area137 Ų
Heavy Atom Count23
Formal Charge0
Complexity585
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Relebactam is indicated in combination with [imipenem] and [cilastatin] for the treatment of complicated urinary tract infections (including pyelonephritis), and complicated intra-abdominal infections caused by susceptible organisms in adults.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Relebactam prevents the hydrolysis of [imipenem], allowing it to exert its bactericidal effect.


5.2 MeSH Pharmacological Classification

beta-Lactamase Inhibitors

Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)


5.3 Absorption, Distribution and Excretion

Absorption

Currently, relebactam is only available as an intravenous product; therefore, there is no relevant absorption data in the literature.


Route of Elimination

Approximately 90-100% of relebactam is renally eliminated.


Volume of Distribution

Relebactam has a volume of distribution of approximately 19 L with both single and steady state dosing.


Clearance

Relebactam has a reported total clearance of approximately 130-150 mL/min (8 L/h). About 30% of the total drug clearance can be attributed to active tubular secretion.


5.4 Metabolism/Metabolites

Relebactam does not undergo significant metabolism and can be found mostly unchanged in human plasma.


5.5 Biological Half-Life

Relebactam has a half-life of 1.2 hours as per official FDA labeling. Values reported in pharmacokinetic studies vary from 1.35-1.8 hours.


5.6 Mechanism of Action

Relebactam is a beta-lactamase inhibitor known to inhibit many types of beta-lactamases including Ambler class A and Ambler class C enzymes, helping to prevent [imipenem] from degrading in the body. Similar to the structurally-related [avibactam], first, relebactam binds non-covalently to a beta-lactamase binding site, then, it covalently acylates the serine residue in the active site of the enzyme. In contrast to some other beta-lactamase inhibitors, once relebactam de-acylates from the active site, it can reform it's 5 membered ring and is capable of rebinding to target enzymes.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed

MSD MERCK CO

Singapore
arrow
BIO Partnering at JPM
Not Confirmed

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2587

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

blank

02

arrow
BIO Partnering at JPM
Not Confirmed

MSD MERCK CO

Singapore
arrow
BIO Partnering at JPM
Not Confirmed

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2840

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

blank

03

arrow
BIO Partnering at JPM
Not Confirmed

MSD MERCK CO

Singapore
arrow
BIO Partnering at JPM
Not Confirmed

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2586

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed

MSD MERCK CO

Singapore
arrow
BIO Partnering at JPM
Not Confirmed

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Exclusivity Code : NCE

Exclusivity Expiration Date : 2024-07-16

Application Number : 212819

Product Number : 1

Exclusivity Details :

blank

02

arrow
BIO Partnering at JPM
Not Confirmed

MSD MERCK CO

Singapore
arrow
BIO Partnering at JPM
Not Confirmed

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Exclusivity Code : GAIN

Exclusivity Expiration Date : 2029-07-16

Application Number : 212819

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Relebactam anhydrous Manufacturers

A Relebactam anhydrous manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Relebactam anhydrous, including repackagers and relabelers. The FDA regulates Relebactam anhydrous manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Relebactam anhydrous API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Relebactam anhydrous manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Relebactam anhydrous Suppliers

A Relebactam anhydrous supplier is an individual or a company that provides Relebactam anhydrous active pharmaceutical ingredient (API) or Relebactam anhydrous finished formulations upon request. The Relebactam anhydrous suppliers may include Relebactam anhydrous API manufacturers, exporters, distributors and traders.

click here to find a list of Relebactam anhydrous suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Relebactam anhydrous NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Relebactam anhydrous as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Relebactam anhydrous API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Relebactam anhydrous as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Relebactam anhydrous and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Relebactam anhydrous NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Relebactam anhydrous suppliers with NDC on PharmaCompass.

Relebactam anhydrous GMP

Relebactam anhydrous Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Relebactam anhydrous GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Relebactam anhydrous GMP manufacturer or Relebactam anhydrous GMP API supplier for your needs.

Relebactam anhydrous CoA

A Relebactam anhydrous CoA (Certificate of Analysis) is a formal document that attests to Relebactam anhydrous's compliance with Relebactam anhydrous specifications and serves as a tool for batch-level quality control.

Relebactam anhydrous CoA mostly includes findings from lab analyses of a specific batch. For each Relebactam anhydrous CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Relebactam anhydrous may be tested according to a variety of international standards, such as European Pharmacopoeia (Relebactam anhydrous EP), Relebactam anhydrous JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Relebactam anhydrous USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty